CompletedNot Applicable

Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States

United States42 participantsStarted 2020-07-01

Plain-language summary

Retrospective, cohort study chart review in patients with hypercoagulable states.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients ≥ 18 year-old * Patients with diagnosis of hypercoagulable state identified by ICD-9/ICD-10 codes * Patients who were prescribed DOACs or VKA for primary or secondary prevention of thrombosis Exclusion Criteria: * Patients with FDA-approved indications of oral anticoagulants including atrial fibrillation or treatment/prevention of thrombotic events unrelated to specified hypercoagulable states * Patients with incomplete electronic medical records

What they're measuring

Rates of thrombotic events during the study period

Timeframe: Jan 1,2015 - Dec 31st, 2019

Rates of hemorrhagic events during the study period

Timeframe: Jan 1,2015 - Dec 31st, 2019

Trial details

NCT IDNCT04565977

SponsorMethodist Health System

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-10

View on ClinicalTrials.gov More Hypercoagulable States trials